Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar

ZIRABEV^™ (bevacizumab), a potential biosimilar to Avastin^®* (bevacizumab), is Pfizer’s second therapeutic oncology biosimilar to receive a positive CHMP opinion in Europe in 2018

Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for ZIRABEV^™ (bevacizumab), a potential biosimilar to Avastin (bevacizumab).¹ ZIRABEV is a monoclonal antibody for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer and persistent, recurrent or metastatic carcinoma of the cervix.²

“If approved, ZIRABEV has the potential to expand access to this life-changing biologic cancer therapy for appropriate patients and healthcare professionals across Europe,” said Joe McClellan, Vice President, Biosimilars Development at Pfizer. “Today’s positive CHMP opinion underscores Pfizer’s strong heritage in oncology and its ongoing commitment to bringing high-quality biosimilars to market, providing additional options for people living with certain cancers.”

https://www.marketscreener.com/PFIZER-23365019/news/Pfizer-Receives-Positive-CHMP-Opinion-for-Oncology-Biosimilar-ZIRABEV-trade-bevacizumab-27756037/